Payment overview · 2025
General Payments
$46.34
2 reported records · 2 companies
Healthcare provider profile · identity verified
Fer Eren, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · GLEN BURNIE, MD · NPI 1497854376
Verified facts
What the public records show
CMS Open Payments records show Fer Eren, M.D. received $46.34 in general payments during 2025 across 2 reported records.
Astellas Pharma US Inc accounted for 58.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 3 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Myrbetriq by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 112 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $27.02 | 58.3% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $19.32 | 41.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $46.34 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $27.02 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $19.32 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $19.32 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 112 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
112 | 20 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 880 | 280 |
| Amlodipine Besylate | Amlodipine Besylate | 820 | 243 |
| Metoprolol Succinate | Metoprolol Succinate | 734 | 219 |
| Losartan Potassium | Losartan Potassium | 565 | 179 |
| Levothyroxine Sodium | Levothyroxine Sodium | 463 | 134 |
| Furosemide | Furosemide | 285 | 96 |
| Lisinopril | Lisinopril | 284 | 86 |
| Metformin Hcl | Metformin Hcl | 284 | 97 |
| Metoprolol Tartrate | Metoprolol Tartrate | 252 | 90 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 251 | 81 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 245 | 88 |
| Pantoprazole Sodium | Pantoprazole Sodium | 237 | 80 |
| Hydrochlorothiazide | Hydrochlorothiazide | 198 | 69 |
| Gabapentin | Gabapentin | 187 | 66 |
| Escitalopram Oxalate | Escitalopram Oxalate | 182 | 60 |
| Tamsulosin Hcl | Tamsulosin Hcl | 178 | 54 |
| Glipizide | Glipizide | 173 | 56 |
| Potassium Chloride | Potassium Chloride | 169 | 65 |
| Pravastatin Sodium | Pravastatin Sodium | 159 | 43 |
| Atenolol | Atenolol | 152 | 48 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 150 | 124 |
| Eliquis | Apixaban | 148 | 50 |
| Jardiance | Empagliflozin | 139 | 41 |
| Omeprazole | Omeprazole | 139 | 39 |
| Famotidine | Famotidine | 133 | 41 |
| Terazosin Hcl | Terazosin Hcl | 131 | 37 |
| Meloxicam | Meloxicam | 124 | 49 |
| Bupropion Xl | Bupropion Hcl | 119 | 43 |
| Clopidogrel | Clopidogrel Bisulfate | 119 | 39 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 116 | 36 |
| Prednisone | Prednisone | 116 | 72 |
| Ozempic | Semaglutide | 112 | 20 |
| Desloratadine | Desloratadine | 105 | 41 |
| Carvedilol | Carvedilol | 104 | 34 |
| Sertraline Hcl | Sertraline Hcl | 96 | 32 |
| Azithromycin | Azithromycin | 90 | 69 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 90 | 29 |
| Alprazolam | Alprazolam | 88 | 28 |
| Allopurinol | Allopurinol | 84 | 25 |
| Ezetimibe | Ezetimibe | 80 | 32 |
| Pregabalin | Pregabalin | 76 | 22 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 72 | 22 |
| Farxiga | Dapagliflozin Propanediol | 70 | 20 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 68 | 37 |
| Trazodone Hcl | Trazodone Hcl | 65 | 29 |
| Zolpidem Tartrate | Zolpidem Tartrate | 65 | 18 |
| Januvia | Sitagliptin Phosphate | 64 | 17 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 64 | 52 |
| Diclofenac Sodium | Diclofenac Sodium | 60 | 26 |
| Ropinirole Hcl | Ropinirole Hcl | 59 | 23 |
| Duloxetine Hcl | Duloxetine Hcl | 57 | 16 |
| Pioglitazone Hcl | Pioglitazone Hcl | 57 | 24 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 56 | 24 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 55 | 17 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 54 | 41 |
| Hydralazine Hcl | Hydralazine Hcl | 54 | 22 |
| Nifedipine Er | Nifedipine | 50 | 15 |
| Glipizide Er | Glipizide | 47 | 14 |
| Methylprednisolone | Methylprednisolone | 47 | 42 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 47 | 19 |
| Ondansetron Hcl | Ondansetron Hcl | 44 | 22 |
| Breo Ellipta | Fluticasone/Vilanterol | 43 | 14 |
| Fluticasone Propionate | Fluticasone Propionate | 43 | 22 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 42 | 29 |
| Labetalol Hcl | Labetalol Hcl | 42 | 12 |
| Topiramate | Topiramate | 42 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 41 | 16 |
| Montelukast Sodium | Montelukast Sodium | 41 | 15 |
| Ventolin Hfa | Albuterol Sulfate | 41 | 24 |
| Mirtazapine | Mirtazapine | 40 | 19 |
| Chlorthalidone | Chlorthalidone | 39 | 12 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 39 | 11 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 39 | 13 |
| Gemfibrozil | Gemfibrozil | 38 | 14 |
| Simvastatin | Simvastatin | 38 | 13 |
| Ibuprofen | Ibuprofen | 37 | 12 |
| Warfarin Sodium | Warfarin Sodium | 37 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 36 | 25 |
| Paroxetine Hcl | Paroxetine Hcl | 35 | 17 |
| Spironolactone | Spironolactone | 35 | 13 |
| Buspirone Hcl | Buspirone Hcl | 32 | suppressed |
| Mounjaro | Tirzepatide | 32 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 31 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 30 | suppressed |
| Synthroid | Levothyroxine Sodium | 30 | suppressed |
| Klor-Con M20 | Potassium Chloride | 29 | suppressed |
| Lovastatin | Lovastatin | 29 | suppressed |
| Clonazepam | Clonazepam | 28 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 27 | 14 |
| Levetiracetam | Levetiracetam | 26 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 26 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 25 | 12 |
| Irbesartan | Irbesartan | 24 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 24 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 24 | 14 |
| Aripiprazole | Aripiprazole | 23 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 23 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 23 | suppressed |
| Xarelto | Rivaroxaban | 23 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 22 | suppressed |
| Verapamil Er | Verapamil Hcl | 21 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 20 | suppressed |
| Ketoconazole | Ketoconazole | 20 | 12 |
| Lorazepam | Lorazepam | 20 | suppressed |
| Sucralfate | Sucralfate | 20 | suppressed |
| Finasteride | Finasteride | 19 | suppressed |
| Fluconazole | Fluconazole | 19 | 14 |
| Trulicity | Dulaglutide | 19 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 18 | suppressed |
| Lansoprazole | Lansoprazole | 18 | suppressed |
| Nystatin | Nystatin | 18 | suppressed |
| Valsartan | Valsartan | 18 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 17 | suppressed |
| Ondansetron Odt | Ondansetron | 17 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 15 | suppressed |
| Colchicine | Colchicine | 15 | suppressed |
| Glimepiride | Glimepiride | 15 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 15 | suppressed |
| Premarin | Estrogens, Conjugated | 15 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 14 | 14 |
| Digoxin | Digoxin | 13 | suppressed |
| Myrbetriq | Mirabegron | 13 | suppressed |
| Novolog Flexpen | Insulin Aspart | 13 | suppressed |
| Amoxicillin | Amoxicillin | 12 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 12 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 12 | suppressed |
| Primidone | Primidone | 12 | suppressed |
| Cephalexin | Cephalexin | 11 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 11 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 11 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 11 | suppressed |
| Hydrocortisone | Hydrocortisone | 11 | suppressed |
| Metolazone | Metolazone | 11 | suppressed |
| Niacin Er | Niacin | 11 | suppressed |
| Nitroglycerin | Nitroglycerin | 11 | suppressed |
| Relistor | Methylnaltrexone Bromide | 11 | suppressed |
| Rexulti | Brexpiprazole | 11 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $46.34 · 2 records | Astellas Pharma US Inc | Ozempic, Rybelsus, Veozah | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Astellas Pharma US Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error